Abbvie Inc.

Abbott Laboratories Corporation

Genentech, Inc.

The Walter and Eliza Hall Institute of Medical Research

The Walter and Eliza Institute of Medical Research

Abbvie Bahamas Limited

Zhi-Fu Tao

Andrew J Souers

Xilu Wang

Le Wang

Gerard M Sullivan

Aaron R Kunzer

Steven Elmore

George A Doherty

Xiaohong Song

Michael D Wendt

Milan Bruncko

Lisa A Hasvold

Todd M Hansen

Laura A Hexamer

Gary T Wang

Robert A Mantei

Hong Ding

Andrew S Judd

Thomas Dale Penning

Cheol-Min Park

Robin R Frey

Yunsong Tong

William J McClellan

Andrew M Petros

David J Madar

Nan-Horng Lin

Keith W Woods

Chunqiu Lai

Julie M Miyashiro

Thomas J Sowin

Vincent L Giranda

Alan S Florjancic

Jianchun Gong

Nathaniel Catron

Guillaume Laurent Lessene

Hing L Sham

Stevan Wakefield Djuric

Keith G Watson

John A Flygare

Anil Vasudevan

Richard F Clark

Michael Michaelides

Chudi Obioma Ndubaku

Jonathan Bayldon Baell

Wayne J Fairbrother

Michael L Curtin

Zhiqin Ji

Yujia Dai

Danette Dudley

Brad E Sleebs

Chinh Thien Bui

Henry Q Zhang

Dennie S Welch

Erwin R Boghaert

Steven W Elmore

Chang H Park

Anthony Mastracchio

David Madar

George Doherty

Peter Colman

Guidong Zhu

Peter Edward Czabotar

Gaoquan Li

Magdalena Przytulinska

Rajeev Goswami

William J Mcclellan

Milan Brunko

Andrew Souers

Brian John Smith

Zhiren Xia

Kurt Deshayes

Cheng Ji

Robert Bruce Diebold

George Nikolakopoulos

Xiahong Song

Akiyo K Claiborne

Aaron K Kunzer

Juliem Miyashiro

Roberto M Risi

Omprakash Reddy Iguturi

Madhu Babu Dabbeeru

Violeta L Marin

Nathaniel D Catron

Scott L Ackler

Keith Geoffrey Watson

Brad Edmund Sleebs

Danette A Dudley

Peter Malcom Colman

Robert B Diebold

Thomas Sowin

Michael Wendt

Laura Hexamer

Lisa Hasvold

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

The present disclosure provides for compounds of formula (I) wherein A, A, A, A, A, A, A, R, R, R, R, R, R, R, R, R, R, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).

Macrocyclic MCL-1 inhibitors and methods of use

Disclosed herein are compounds that inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases using the compounds. One embodiment of such compounds is 4-(4-{[2-(4-chloro-2-fluorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide.

Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseases

Disclosed are compounds of Formula (IIa), wherein R, R, R, R, R, R, R, and Rare as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).

Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors

Disclosed are compound of Formula (Ia), wherein R, R, R, J, Q, X, Y and Z are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (Ia).

Pyridine CDK9 kinase inhibitors

Compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds, and methods of treating diseases involving overexpressed or unregulated Mcl-1 protein are disclosed.

7-substituted indole Mcl-1 inhibitors

Disclosed are compound of Formula (Ia), wherein R, R, and Rare as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions, comprising one or more compounds of Formula (Ia).

Substituted pyrrolo[2,3-d]pyrimindines as CDK9 kinase inhibitors

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.

Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases

Growing community of inventors

Gurnee, IL, United States of America

Zhi-Fu Tao